Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
for B-cell Acute Lymphoblastic Leukemia
14 locations incl. Los Angeles
Sponsor: Cellectis S.A.
Sex: All·Age: 15 - 50
Code: NCT04150497·Phase 1, Phase 2·Recruiting